| Faculty | Pictures(Some presentations are available for viewing. Please click the 
icon to view the slides from that talk.)
| Friday, November 11, 2005 | |||
| 8:15 am - 9:00 am |
Keynote Address: Overcoming Immunosuppression / Tolerance in Cancer Patients James Allison, PhD Memorial Sloan-Kettering Cancer Center |
||
| 9:00 am - 11:45 am |
Plenary Session: Overcoming Immunosuppression / Tolerance in Cancer Patients
|
||
| 9:00 am - 9:30 am |
How Host Cells Sink Anti-tumor Responses by Competing
for Activating Cytokines Nicholas P. Restifo, MD National Cancer Institute |
||
| 9:30 am - 9:45 am |
IL-2 Paradoxically Controls Tolerance and Immunity to a
Tumor/Self-antigen Paul A. Antony, MD National Cancer Institute - Surgery Branch |
||
| 9:45 am - 10:15 am |
Immunological Targeting of Tumor Stroma: Destruction of Cancer
Variants and the Immunosuppressive Microenvironment Hans Schreiber, MD, PhD University of Chicago |
||
| 10:15 am - 10:30 am |
Pharmacological Inhibition of the Immunomodulatory Enzyme
Indoleamine 2,3-Dioxygenase (IDO) Cooperatively Leverages
Cytotoxic Chemotherapy Alexander J. Muller, PhD Lankenau Institute for Medical Research |
||
| 11:00 am - 11:30 am |
Recruitment of High Avidity Antigen Specific T Cells with T
Regulatory Cell Modulation Elizabeth M. Jaffee, MD Johns Hopkins University |
||
| 11:30 am - 11:45 am |
Intra-tumoral IL-12 + GM-CSF Microsphere Therapy Induces
Activation of Tumor-associated T-Effector/Memory Cells, Exodus of
CD4+ CD25+ T-Suppressors and Infiltration of CD8+ T-Effectors Nejat K. Egilmez, PhD University of Louisville |
||
| 1:00 pm - 3:00 pm |
Plenary Session: New Agents in Development
|
||
| 1:00 pm - 1:15 pm | Tumor Therapy with Proteasome Inhibitor Bortezomib (Velcade, PS-
341) Plus Death Receptor (DR5) Agonist Antibody MD5.1 Anil Shanker, PhD National Cancer Institute |
||
| 1:15 pm - 1:45 pm | The Role of Invariant NKT Cells in Enhancing Antigen Specific
T and B Cell Responses Vincenzo Cerundolo, MD, PhD University of Oxford |
||
| 1:45 pm - 2:00 pm | Identification of a Well-tolerated Outpatient Regimen of
Interleukin-21 in Patients with Metastatic Melanoma and
Renal Cell Carcinoma John A. Thompson, MD University of Washington |
||
| 2:00 pm - 2:15 pm | Proteasome Inhibition Upregulates the Cell Surface Expression of
Receptors for IFN-ã and TNF-á on Murine Neuroblastoma Cells and
Enhances the Proapoptotic and Overall Antitumor Activity of
Systemic Cytokine Therapy in Murine Neuroblastoma Tumors Tahira Khan, PhD National Cancer Institute |
||
| 2:15 pm - 2:45 pm | Building Up Molecularly Defined Vaccines for Immunotherapy of Cancer Pedro J. Romero, MD Ludwig Institute for Cancer Research |
||
| 2:45 pm - 3:00 pm | Induction of Therapeutic Breast Cancer Immunity with an IL-2
Immunotoxin Keith Knutson, PhD Mayo Clinic |
||
| 3:30 pm - 5:15 pm |
Concurrent Session I: Immune Monitoring
|
||
| 3:30 pm - 4:00 pm | Monitoring Mage Vaccination. Insights into Mechanisms of Tumor Regression Pierre Coulie, MD Universite Catholique de Louvain |
||
| 4:00 pm - 4:15 pm | Metastatic Prostate Cancer Patients Treated with GVAX® Vaccine for
Prostate Cancer Develop Immunoreactivity to Filamin: Role of
Filamin in Prostate Cancer Metastasis Manjula Chinnappa, PhD Cell Genesys |
||
| 4:15 pm - 4:45 pm | Factors that Influence Responses to Adoptive Cancer Immunotherapy Paul F. Robbins, PhD National Cancer Institute - Surgery Branch |
||
| 4:45 pm - 5:00 pm | Systematic Analysis of Anti-NY-ESO-1 T Cell Responses Reveals
Striking HLA-dependent Immunodominance Weisan Chen, PhD Ludwig Institute for Cancer Research |
||
| 5:00 pm - 5:15 pm | GM-CSF Can Modulate the Migratory Phenotype of Vaccine-induced
T Cells by Enhancing CXCR3 Expression Il-Kang Na, MD Charité, Campus Benjamin Franklin |
||
| 3:30 pm - 5:15 pm |
Concurrent Session II: Cytokines: Biology and Therapeutics
|
||
| 3:30 pm - 3:45 pm | Microarray Analysis for Monitoring the Response to Interferon Eleonora Arico’, MD National Institute of Health |
||
| 3:45 pm - 4:00 pm | Interleukin-29 Mediates Potent Anti-tumor Activity in the RenCA
Model of Renal Cell Carcinoma Pallavur V. Sivakumar, PhD Zymogenetics, Inc. |
||
| 4:00 pm - 4:15 pm | Intratumoral Injection of IL-2 Plasmid Followed by
Electroporation for Cancer Therapy Holly Horton, PhD Vical, Inc. |
||
| 4:15 pm - 4:45 pm | A CWG 3-arm Phase II Trial of GP100 (209-2M) Peptide + High Dose
Interleukin-2 in HLA-A2+ Advanced Melanoma Patients Jeffrey A. Sosman, MD Vanderbilt University |
||
| 4:45 pm - 5:15 pm | Expansion of CD4 + CD25 + Regulatory T Cells During Lymphopenia
and Following IL2 Therapy Crystal Mackall, MD National Cancer Institute - Pediatric Oncology |
||
| 3:30 pm - 5:15 pm |
Concurrent Session III: Novel Approaches to Monoclonal Antibodies
|
||
| 3:30 pm - 4:00 pm | Stepping Stones Toward Cancer Immunotherapy Alan L. Epstein, MD, PhD University of Southern California, Keck School of Medicine |
||
| 4:00 pm - 4:15 pm | Phase I Trial of Siplizumab in CD2-positive Lymphoproliferative
Disease John Janik, MD National Cancer Institute - Metabolism Branch |
||
| 4:15 pm - 4:45 pm | New Directions for Monoclonal Antibody Therapy Louis M. Weiner, MD Fox Chase Cancer Center |
||
| 4:45 pm - 5:00 pm | Genetic Immunization and Antibody Generation in Research Animals
by Intravenous Delivery of Plasmid DNA Mary Kay Bates, MS Mirus Bio Corporation |
||
| 5:00 pm - 5:15 pm | A Phase I Trial of Interleukin-12 with Trastuzumab and Paclitaxel
for HER2-overexpressing Malignancies Julie Roda Ohio State University |
||
| Saturday, November 12, 2005 | |||
| 8:15 am - 9:00 am |
Keynote Address: Large-scale Genomic Methods to Dissect Cancer Phenotypes Garrett Hampton, PhD Genomics Institute |
||
| 9:00 am - 11:45 am |
Plenary Session: Genomics / Proteomics of Tumors and the Host Response
|
||
| 9:00 am - 9:30 am | Gene Profiling of BCC Treated with the Immunomodifier Imiquimod
(ALDARA ™) Reveals Key Signatures of Tumor Rejection Monica Panelli, PhD National Institutes of Health |
||
| 9:30 am - 9:45 am | High Mobility Group B1 Matures Dendritic Cells and is a DAMP,
Elevated in the Serum of Hepatoma Patients with Chronic Hepatitis C
and Diminishing Following Resection and Orthotopic Liver
Transplantation or Radiofrequency Ablation Michael T. Lotze, MD University of Pittsburgh |
||
| 9:45 am - 10:00 am | Inflammatory Protein Profile During Systemic High Dose
Interleukin-2 Administration Leonardo Rossi, PhD National Institutes of Health - Immunogenetics Section |
||
| 10:00 am - 10:30 am | A Novel Two-gene Expression Ratio that Predicts Clinical Outcome
in Breast Cancer Patients Treated with Tamoxifen Dennis C. Sgroi, MD Harvard Medical School |
||
| 11:00 am - 11:15 am | Signaling Networks in Cutaneous Melanoma Metastasis Identified by
cDNA Microarrays Ulrich R. Hengge, MD University of Dusseldorf |
||
| 11:15 am - 11:45 am | Proteomic Profiling of Cancer Tissues: Moving Towards
Individualized Therapy Julia Wulfkuhle, PhD George Mason University |
||
| 1:00 pm - 2:20 pm |
Presidential Session
|
||
| 1:00 pm - 1:20 pm | Characterization of Primary and Immune Escape Variant of HER-
2/NEU Overexpressing Mouse Mammary Carcinoma Masoud H. Manjili, PhD Virginia Commonwealth University |
||
| 1:20 pm - 1:40 pm | CD4 Cells can be More Efficient at Tumor Rejection than CD8 Cells Ainhoa Pérez-Diez, PhD National Institutes of Health |
||
| 1:40 pm - 2:00 pm | WT1-Peptide Vaccination in Patients with Acute Myeloid Leukemia
Shows High Immunogenicity Associated with Clinical Activity Anne Letsch, MD Charité, Campus Benjamin Franklin |
||
| 2:00 pm - 2:20 pm | Mechanism of Caspase Independent Activation Induced Cell Death of
Human Primary Cytotoxic T Lymphocytes: Implications for Cancer
Immunotherapy Arvind Chhabra, PhD University of Connecticut Health Center |
||
| 2:45 pm - 4:30 pm |
Concurrent Session I: Cellular Therapies for Solid and Liquid Tumors
|
||
| 2:45 pm - 3:15 pm | Improving Immunotherapy Targeted at Subdominant Tumor Antigens Helen E. Heslop, MD Baylor College of Medicine |
||
| 3:15 pm - 3:45 pm | Treatment of Patients with Metastatic Melanoma by Infusion of
Anti-MART-1 TCR-Gene Engineered Lymphocytes Richard Morgan, PhD National Cancer Institute - Surgery Branch |
||
| 3:45 pm - 4:00 pm | TCR in Renal Cell Carcinoma: Models, Monitoring and Therapy Dolores J. Schendel, MD, PhD Institute of Molecular Immunology |
||
| 4:00 pm - 4:15 pm | Hematopoietic Stem Cell Transplant with Lymphodepletion Augments
T Cell-based Adoptive Immunotherapy Claudia Wrzesinski, PhD, DMV National Cancer Institute |
||
| 4:15 pm - 4:30 pm | Ex-vivo Heat Shock Protein 70-Peptide-activated, Autologous
Natural Killer Cells Adoptive Therapy: From the Bench to the Clinic Valeria Milani, MD, PhD Ludwig Maximilian University |
||
| 2:45 pm - 4:30 pm |
Concurrent Session II: Signal Transduction Inhibitors
|
||
| 2:45 pm - 3:00 pm | Prostaglandin E2-mediated Receptor Signaling and Control of
Breast Tumor Metastasis by Natural Killer Cells Namita Kundu, PhD University of Maryland School of Medicine |
||
| 3:00 pm - 3:15 pm | COX-2 Inhibition in Tumor Cells Blocks Arginase I Induction in
Myeloid Supperssor Cells Augusto Ochoa, MD Louisiana State University |
||
| 3:15 pm - 3:30 pm | Isoform-specific Gene Targeting for Cancer Therapy with Small
Interfering RNA (siRNA) Lin Zhang, MD University of Pennsylvania |
||
| 3:30 pm - 4:00 pm | A Novel Mechanism of Herceptin Resistance and Counteracting
Strategies Dihua Yu, MD, PhD MD Anderson Cancer Center |
||
| 4:00 pm - 4:30 pm | The Insulin-like Growth Factor Receptor-I as a Strategic Target
for Antibody Therapeutics Against Cancer Michael G. Atkins, MD Beth Israil Deaconess Medical Center |
||
| 4:45 pm - 5:45 pm |
Poster Discussion Session
|
||
| 4:45 pm - 5:00pm | NK Cell/Macrophage Role in Antitumor Immunity Jerome Ritz, MD Dana-Farber Cancer Institute |
||
| 5:00 pm - 5:15 pm | Novel Antigens for Tumor Immunotherapy Jonathan Skipper, PhD Ludwig Institute for Cancer Research |
||
| 5:15 pm - 5:30 pm | New Tumor Vaccine Approaches Thomas F. Gajewski, MD, PhD University of Chicago |
||
| 5:30 pm - 5:45 pm | Cytokines and Tumor Immunology Jon M. Wigginton, MD National Cancer Institute |
||
| Sunday, November 13, 2005 | |||
| 8:00 am - 8:45 am |
Richard V. Smalley, MD Memorial Lectureship Steven A. Rosenberg, MD, PhD National Cancer Institute |
||
| 8:45 am - 11:00 am |
Plenary Session: Turning Immunization into Tumor Regression: Obstacles and Strategies
|
||
| 8:45 am - 9:15 am | Molecular Manipulation of the Anti-tumor Immune Response Drew M. Pardoll, MD, PhD Johns Hopkins University |
||
| 9:15 am - 9:30 am | Evaluation of Myeloid Suppressive Cells in Peripheral Blood of
Melanoma Patients and Their Modualtion by a Heat-shock
Protein -96 and GM-CSF-based Vaccine Licia Rivoltini, MD Istituto Nazionale Tumori |
||
| 9:30 am - 9:45 am | Potent Immunity Achieved by Targeted, Sequential Administration
of Recombinant DNA Vectors and Anchor-modified Epitope Peptides Adrian Bot, MD, PhD MannKind Corporation |
||
| 9:45 am - 10:00 am | Polarized DC1-based Therapeutic Cancer Vaccines Pawel Kalinski, MD, PhD University of Pittsburgh |
||
| 10:00 am - 10:15 am | Rescuing Anti-melanoma CD4+ Responses with Type-1 Polarized
Dendritic Cells: Essential Roles of Extended IL-12 Family Members Amy Wesa, PhD University of Pittsburgh |
||
| 10:15 am - 10:30 am | In Situ Targeting of Antigen Presenting Cells within Secondary
Lymphoid Organs as a Means to Control Immune Responses Kent A. Smith, MA MannKind Corporation |
||
| 10:30 am - 11:00 am | Making Vaccines Work: Translating Basic and Preclinical
Immunology into Human Immunotherapies Nicholas P. Restifo, MD National Cancer Institute |
||
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
